Compressed solid composition for MRI
The development of a single-chamber compressed solid composition for Mangoral, utilizing non-hygroscopic excipients and low humidity conditions, addresses the challenges of incorrect administration and hospital stays associated with two-sachet formulations, enabling easy and effective oral MRI contrast agent use.
Patent Information
- Application Number
- CN202080052687.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-06-07
- Filing Date
- 2020-06-08
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2040-06-08
AI Technical Summary
Current formulations of Mangoral, a manganese-based oral contrast agent for MRI, are provided in two separate sachets, which can lead to incorrect administration and increased hospital stays, necessitating a single-chamber compressed solid composition for ease of handling and reduced risk of incorrect administration.
A single-chamber compressed solid composition is developed by preparing manganese (II) chloride in a water-soluble tablet form under low relative humidity conditions, using carefully selected non-hygroscopic excipients to ensure stability and rapid dissolution in water.
The composition allows for easy handling and administration at home, reducing the risk of incorrect dosing and hospital stays, while maintaining high imaging quality by ensuring rapid and complete dissolution in water without agitation.
Smart Images

Figure BDA0003480388920000021 
Figure BDA0003480388920000091 
Figure BDA0003480388920000101
Abstract
Description
Technical Field
[0001] The present invention relates to a compressed solid composition for magnetic resonance imaging (MRI), its preparation and its use for the preparation of an oral solution, said composition comprising a physiologically acceptable manganese (II) compound. Background Art
[0002] Manganese is one of the most abundant metals on earth and is a component of more than 100 different minerals. In addition to being an essential trace element associated with metabolic processes in the body, manganese is also a paramagnetic metal that has characteristics similar to gadolinium in terms of T1-weighted (T1-w) magnetic resonance imaging (MRI). Manganese in the form of manganese (II) chloride tetrahydrate is the active substance in Mangoral, a targeted oral contrast agent indicated for hepatobiliary MRI. Under physiological conditions, manganese is poorly absorbed from the intestine after oral intake, but by using specific absorption enhancers (L-alanine and vitamin D3), sufficiently high concentrations can be obtained in the liver to achieve significant signal enhancement effects. In the liver, manganese is exposed to a very high first-pass effect, up to 98%, which prevents the metal from reaching the systemic circulation, thereby reducing the number of systemic side effects. Manganese is one of the least toxic trace elements, and due to its good safety profile, it may be an attractive alternative to gadolinium-based contrast agents for patients undergoing liver MRI evaluation in the future, especially for patients with severe renal insufficiency or acute kidney injury.
[0003] Liver metastases are the most common type of malignant focal liver lesions. Metastasis to the liver often occurs in progressive cancer disease and is associated with significantly reduced survival. In fact, the liver is one of the most common sites of metastasis and is often the first site of metastasis. Approximately 70% of all patients with colorectal cancer will develop liver metastases at some point in their lifetime, and one-third of these will have metastases confined to the liver. Early detection and localization of liver metastases is critical to optimize patient management.
[0004] Mangoral is the first contrast agent in the world to receive Orphan Drug Designation from the FDA for liver MRI in patients for whom gadolinium-based contrast agents may not be medically recommended or cannot be administered.
[0005] Mangoral is administered orally and consists of a combination of manganese and an absorption enhancer that increases manganese absorption in the small intestine, which is a prerequisite for high manganese uptake into liver tissue, which is the best condition for obtaining high imaging quality. Manganese is a natural trace element, and after absorption from the gastrointestinal tract, it is effectively absorbed by liver cells. Due to the retention of manganese in hepatocytes and its paramagnetic properties, the contrast agent significantly enhances liver tissue in MR imaging, while liver metastases do not accumulate manganese. Therefore, liver metastases will become clearly detectable for liver tissue enhanced on MR images.
[0006] Currently, Mangoral is provided as a two-chamber powder formulation, with the manganese salt in one sachet and one or more absorption enhancers in a separate sachet, as the powders are considered incompatible. Both sachets are then emptied into a glass of water to provide an oral MRI solution.
[0007] While two-chamber formulations perform well, a compressed solid composition comprising the active ingredient of Mangoral would allow for ease of handling of the compressed solid composition by the patient and would potentially allow for home administration with a lower risk of incorrect administration of the contrast composition and thereby reduce hospital stays associated with MRI. Therefore, there is a need in the art to provide a single-chamber formulation of Mangoral, particularly in the form of a compressed solid composition. Summary of the invention
[0008] The inventors of the present invention have found that the active ingredient of Mangoral can be prepared in a single chamber formulation as a compressed solid composition for MRI suitable for preparing an oral solution. By preparing the compressed solid composition at low relative humidity (rH) such as below 25% rH and by carefully selecting water-soluble excipients with low hygroscopicity, the inventors of the present invention have successfully prepared water-soluble tablets and effervescent tablets containing manganese (II) chloride.
[0009] In a first aspect, a magnetic resonance imaging (MRI) contrast composition is provided, the composition comprising: a physiologically acceptable manganese (II) compound, one or more absorption enhancers and one or more water-soluble excipients, wherein the compressed solid composition is a compressed solid composition suitable for preparing an oral solution.
[0010] In a second aspect, there is provided a method for preparing a compressed solid composition as defined herein, wherein the method comprises the following steps:
[0011] a. providing a physiologically acceptable manganese (II) compound, optionally in the form of particles, and optionally drying the physiologically acceptable manganese (II) compound;
[0012] b. providing one or more absorption enhancers;
[0013] c. providing one or more water-soluble excipients that allow compression;
[0014] d. mixing the physiologically acceptable manganese (II) compound with the one or more absorption enhancers and the one or more water-soluble excipients to provide a water-soluble mixture; and
[0015] e. compressing the water soluble mixture to provide a compressed solid composition as defined herein.
[0016] In a third aspect there is provided a compressed solid composition prepared by a process as defined herein.
[0017] In a fourth aspect, a method for preparing an oral MRI solution is provided, the method comprising:
[0018] a. providing a compressed solid composition as defined herein,
[0019] b. Provide adequate water, and
[0020] c. adding the compressed solid composition to the water,
[0021] Thereby forming the oral MRI solution. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1: Effect of temperature on effervescent tablets (water volume 200 ml). The effervescent tablets disintegrate rapidly and the dissolution time decreases with increasing temperature.
[0023] Figure 2: Disintegration time to a clear solution under different volumes of water (at 20°C) for the effervescent tablet and two-chamber powder formulation, respectively. The effervescent tablets showed significantly faster and therefore superior solubility and disintegration rates compared to the two-chamber powder formulation.
[0024] Figure 3: Visual inspection of a glass of water into which (A) an effervescent tablet or (B) a two-chamber powder formulation has been placed. (A) The effervescent tablet provides a clear solution without any precipitate after 5 minutes; (B) the two-chamber powder formulation provides a clear solution with precipitate after 5 minutes.
[0025] definition
[0026] The term "water-soluble" is used herein to describe compounds that dissolve in water at room temperature, such as about 25°C. The degree of water solubility ranges widely, from infinitely soluble (unrestricted) (completely miscible) (such as ethanol in water) to poorly soluble (such as silver chloride in water). The term "insoluble" is generally applied to compounds that are poorly soluble or very poorly soluble.
[0027] The term "water-insoluble" is used herein to describe compounds that are insoluble in water at room temperature, such as about 25°C.
[0028] Many other descriptive terms are also used to quantify the degree of solubility of a given solute (i.e., a compound that undergoes a dissolution process):
[0029]
[0030] The water solubility of a given solute is typically temperature dependent. Depending on the nature of the solute, the solubility may increase or decrease with temperature. For most solids and liquids, their solubility in water increases with temperature.
[0031] The term "poor solubility in cold water" is used herein to describe a compound that does not completely dissolve in cold water, such as a glass of water, such as between about 2°C to about 15°C.
[0032] The terms "slowly dissolving" and "very slowly dissolving" are used herein to describe compounds with a low dissolution rate in water. "Slow rate" in the context of the present invention means any rate that does not allow the compound to completely dissolve in water (such as a glass of water) in 8 minutes or less.
[0033] The term "hygroscopic" is used herein to describe a compound that absorbs water by absorption, adsorption, or a combination of both processes at a relative humidity (rH) between 40% and 60% to any significant extent, such as to an extent where the mass and / or volume of the compound increases by about 5% or more over a period of time, such as after about 1 hour.
[0034] The term "relative humidity" or "rH" refers to the percentage ratio of the partial pressure of water vapor to the equilibrium vapor pressure of water at a given temperature.
[0035] The term "non-hygroscopic water-soluble" is used herein to describe compounds that are not hygroscopic as defined herein and at the same time are water-soluble as defined herein.
[0036] The term "absorption enhancer" is used interchangeably herein with the term "uptake enhancer" and refers to a compound capable of enhancing the transport of manganese across the gastrointestinal membrane. These compounds are well known in the art, for example from WO 96 / 05867, and include physiologically tolerated reducing compounds containing an α-hydroxy ketone group, physiologically tolerated acids or salts thereof containing an α- and / or β-hydroxy or amino group, and / or vitamin D.
[0037] As used herein, the term "effervescent couple" refers to a pair of pharmaceutically acceptable excipients, one of which is a basic component and the other is an acidic component. The basic component releases carbon dioxide when it comes into contact with the acidic component and water. An example of a basic component is bicarbonate.
[0038] The term "clear solution" as used herein refers to a solution that appears clear upon visual inspection under daylight. DETAILED DESCRIPTION
[0039] The present disclosure provides a magnetic resonance imaging (MRI) contrast composition, comprising: a physiologically acceptable manganese (II) compound, one or more absorption enhancers and one or more water-soluble excipients, wherein the compressed solid composition is a compressed solid composition suitable for preparing an oral solution.
[0040] Difficulties in the production of compressed hygroscopic solids
[0041] The design and manufacture of pharmaceutical compressed solids, such as tablets, is a complex, multi-stage process in which several parameters need to be carefully controlled, namely that the correct amount of the drug substance in the proper formulation is delivered at the right time, at the right rate, and in the desired location, and that its chemical integrity is protected throughout the process.
[0042] The main objectives of the tablet manufacturing process include:
[0043] Formulate tablets that are strong and difficult to withstand mechanical shocks encountered during manufacturing, packaging, transportation, distribution and use.
[0044] Formulate tablets of uniform weight and drug content.
[0045] Formulate tablets with the bioavailability required according to the indication.
[0046] Formulate tablets that are chemically and physically stable over a long period of time.
[0047] Formulate tablets with clean product characteristics (without any tablet defects).
[0048] During tablet compression, it is generally preferred to have a relatively high moisture content so that a higher tablet hardness can be produced at a lower compression force. However, there are limitations because higher moisture content tends to produce two undesirable results:
[0049] Increased moisture content will result in decreased powder flow rate, thereby increasing the adhesion of powder particles, which leads to unstable tablet weight uniformity.
[0050] Increased moisture results in an increase in viscosity defects, which is particularly challenging for embossing compression tools because there are more pockets where powder can stick.
[0051] About chemical stability, relatively low moisture content is preferred to reduce the degree of drug degradation, make microbial growth more difficult and prevent compound clogging.For example, effervescent tablets are very sensitive to moisture content.The chemical reaction between organic acid and inorganic base is autocatalytic, and it produces gaseous carbon dioxide and water.Therefore, very low moisture content is needed to prevent the reaction from starting, but once started, the water produced by the reaction further promotes the reaction until the component is exhausted.
[0052] Tablet production can be very difficult for hygroscopic materials and requires careful optimization of excipient selection as well as the tableting process.
[0053] Hygroscopicity
[0054] Hygroscopicity is the phenomenon of attracting and holding water molecules from the surrounding environment, usually at normal or room temperature. This is achieved by absorption or adsorption, in which the adsorptive substance undergoes a physical change. This may be an increase in the substance's volume, boiling point, viscosity, or other physical characteristics or properties, as water molecules may become suspended between the substance's molecules during the process.
[0055] The total amount of water that can be absorbed by a hygroscopic material will be a function of the temperature and humidity of the atmosphere in which the material is located, and will ultimately be determined by the adsorption isotherm of the system.
[0056] The term "hygroscopic" is used herein to describe a compound that absorbs water by absorption, adsorption, or a combination of both processes at a relative humidity (rH) between 40% and 60% to any significant extent, such as to an extent where the mass and / or volume of the compound increases by about 5% or more after a period of time, such as after about 1 hour.
[0057] Relative humidity (rH)
[0058] Poor environmental control, particularly in terms of air humidity, can directly impact pharmaceutical production lines in a number of ways. Humidity levels below 45% rH will allow electrostatic charges to build up in machinery and materials. This can have a significant impact where flammable solvents are used in the process, making electrical connections between machines important. Low humidity can also cause the product to dry out, affecting its performance. Charge buildup on powders can cause poor powder flow, and charged products can cause them to stick to each other, leading to packaging issues.
[0059] High humidity can also cause the product to absorb moisture during production and final packaging. In the case of a product that is chronically sensitive to moisture, the product will degrade over time when packaged under the wrong conditions.
[0060] The issue of humidity is complex because different steps in the manufacturing process may have different requirements for the moisture content of the atmosphere.
[0061] Air conditioning and handling equipment based on a refrigeration cycle - a heating, ventilation and air conditioning (HVAC) system - is usually set up to condition the working environment to maintain relative humidity levels between 40% and 60%, and temperatures around 21°C-25°C.
[0062] In the context of the present disclosure, it is important to control the relative humidity of the atmosphere to below 35% rH, such as below 34%, such as below 33%, such as below 32%, such as below 31%, such as below 30%, such as below 29%, such as below 28%, such as below 27%, such as below 26%, such as below 25%, such as below 24%, such as below 23%, such as below 22%, such as below 21%, such as below 20%, such as below 19%, such as below 18%, such as below 17%, such as below 16%, such as below 15%, such as below 14%, such as below 13%, such as below 12%, such as below 11%, such as below 10%, in all tablet production areas.
[0063] In one embodiment, relative humidity (rH) is maintained at less than 30%. In one embodiment, relative humidity (rH) is maintained at less than 25%. In one embodiment, relative humidity (rH) is maintained at less than 20%. In one embodiment, relative humidity (rH) is maintained at less than 15%, such as less than 10%.
[0064] Relative humidity levels below 40% can be achieved with a rotary desiccant dryer. These machines have been in use for many years and can be sized according to the work area that needs to be dried. They work by passing an ambient air stream over a solid desiccant (typically silica gel) located within a rotating wheel or bed. The outlet air from a rotary dryer can have a relative humidity of 1% or less, and it may be necessary to blend this air stream with another stream to achieve the humidity level required for a particular manufacturing equipment or process. Therefore, flow control is important. The water absorbed from the air by the desiccant is released by the desiccant bed, rotating into the hot air stream. The resulting humid air is usually exhausted outside the building.
[0065] Pharmaceutical excipients
[0066] Pharmaceutical excipients are substances formulated with the active ingredients of a medicament that are included for the following purposes: long-term stabilization, bulking up solid formulations containing small amounts of effective active ingredients (hence often referred to as "bulking agents," "fillers," or "diluents"), or to impart therapeutic enhancements to the active ingredient in the final dosage form, such as, but not limited to, promoting drug absorption, reducing viscosity, or enhancing solubility. Pharmaceutical excipients may also be used during the manufacturing process to aid in the handling of the active substance involved (such as by promoting powder flowability or non-sticking properties), in addition to aiding in vitro stability (such as preventing denaturation or aggregation during the expected shelf life).
[0067] It will be appreciated by those skilled in the art that while some excipients are preferred for inclusion and some are not preferred in the compositions as disclosed herein, it is possible to produce tablets containing non-preferred excipients if the relative amounts of the excipients are carefully controlled. Some excipients may contain about 5% moisture and are therefore non-preferred, but may still be included in low amounts if other excipients included are non-hygroscopic and dry. The following section summarizes different excipient groups according to the present disclosure, and an indication of which excipients are preferably included in a mixed blend to provide a compressed solid composition having the desired properties.
[0068] In one embodiment, there is provided a compressed solid composition as defined herein, wherein the one or more water-soluble excipients are non-hygroscopic water-soluble excipients. In one embodiment, the one or more water-soluble excipients are selected from: non-hygroscopic fillers, non-hygroscopic binders, non-hygroscopic disintegrants and non-hygroscopic lubricants.
[0069] The excipients of the present disclosure should collectively allow:
[0070] - Efficiently produce a plurality of compressed solid compositions (tablets) that are uniform in size and that all contain substantially the same amount of active ingredients (manganese (II) compound and one or more absorption enhancers).
[0071] • The compressed solid composition dissolves rapidly and substantially completely in water without agitation or stirring.
[0072] • Forms a clear oral solution with a taste acceptable for oral consumption.
[0073] Filler / Diluent : A "filler" or "diluent" according to the present disclosure is preferably a water-soluble and non-hygroscopic filler. In one embodiment, a compressed solid composition as defined herein is provided, wherein the non-hygroscopic filler is selected from: isomalt; lactose, such as spray-dried lactose, alpha-lactose or beta-lactose; maltitol; maltose; and mannitol.
[0074] Dextrin and lactitol may be used as alternative fillers in small amounts, but typically contain 5% moisture and are therefore not preferred for inclusion.
[0075] Dextrose mixture (dextrate), dextrose, fructose, hypromellose, maltodextrin, sucrose, sorbitol and xylitol are also water-soluble fillers, but are hygroscopic and are therefore not preferably included in the compressed solid composition as defined herein. In one embodiment, a compressed solid composition as defined herein is provided, wherein the compressed solid composition does not contain a hygroscopic filler selected from the group consisting of dextrose mixture, dextrose, fructose, hypromellose, maltodextrin, sucrose, sorbitol and xylitol.
[0076] In one embodiment, the compressed solid composition does not contain a water-insoluble filler. In one embodiment, the water-insoluble filler is selected from: calcium carbonate, calcium phosphate (e.g., basic calcium phosphate, calcium hydrogen phosphate, dicalcium phosphate), calcium silicate, powdered cellulose, cellulose acetate, magnesium carbonate, magnesium oxide, medium-chain triglycerides, microcrystalline cellulose, silicified microcrystalline cellulose, polymethacrylate, starch, calcium sulfate, and pregelatinized starch. In one embodiment, a compressed solid composition as defined herein is provided, wherein the compressed solid composition does not contain a water-insoluble filler selected from: calcium carbonate; calcium phosphate, such as basic calcium phosphate, calcium hydrogen phosphate, or dicalcium phosphate; calcium silicate; cellulose powder; cellulose acetate; magnesium carbonate; magnesium oxide; medium-chain triglycerides; microcrystalline cellulose; silicified microcrystalline cellulose; polymethacrylate; starch; calcium sulfate; and pregelatinized starch.
[0077] Binder : The "binding agent" according to the present disclosure is preferably a water-soluble and non-hygroscopic binding agent. In one embodiment, the water-soluble and non-hygroscopic binding agent is selected from: hydroxyethyl methylcellulose, maltose, povidone and dextrin. In one embodiment, the binding agent is povidone.
[0078] Sodium carboxymethylcellulose, dextrose mix, dextrose, hydroxyethylcellulose, hydroxypropylcellulose, maltodextrin, poloxamers, polydextrose and sucrose may be used in low amounts as alternative water-soluble binders, but they are all hygroscopic and therefore not preferred.
[0079] Gum arabic, hypromellose, methylcellulose and sodium alginate are water soluble but dissolve very slowly in water and are not very useful. Pregelatinized starch, inulin, agar, gelatin, starch, alginic acid, cellulose acetate phthalate, ethyl cellulose, hydrogenated vegetable oils, magnesium aluminum silicate, microcrystalline cellulose and polymethacrylates have poor solubility in cold water and are therefore not preferred binders.
[0080] In one embodiment, there is provided a compressed solid composition as defined herein, wherein the compressed solid composition does not comprise a poorly water-soluble binder selected from the group consisting of gum arabic, hypromellose, methylcellulose, sodium alginate, pregelatinized starch, inulin, agar, gelatin, starch, alginic acid, cellulose acetate phthalate, ethylcellulose, hydrogenated vegetable oils, magnesium aluminum silicate, microcrystalline cellulose and polymethacrylate.
[0081] Disintegrants : "Disintegrants" are known in the art to swell and dissolve when wetted, causing compressed pharmaceutical compositions (such as tablets) to break apart.
[0082] Povidone is a water soluble disintegrant, but not a very strong disintegrant.In one embodiment, there is provided a compressed solid composition comprising a non-hygroscopic disintegrant, wherein the non-hygroscopic disintegrant is povidone.
[0083] Carboxymethylcellulose calcium, croscarmellose sodium and crospovidone are insoluble in water but are very strong disintegrants and can be used at very low levels and are preferred. In one embodiment, there is provided a compressed solid composition as defined herein, further comprising a water-insoluble disintegrant. In one embodiment, the water-insoluble disintegrant is selected from: carboxymethylcellulose calcium; croscarmellose sodium; and crospovidone.
[0084] Sodium carboxymethylcellulose and hydroxypropylcellulose are water soluble disintegrants but are not preferred because they are hygroscopic. In one embodiment, the compressed solid composition does not comprise a hygroscopic disintegrant selected from sodium carboxymethylcellulose and hydroxypropylcellulose.
[0085] Methylcellulose, sodium alginate, pregelatinized starch, starch, alginic acid, calcium alginate, magnesium aluminum silicate, microcrystalline cellulose, polacrilin potassium and sodium starch glycolate can be used as disintegrants but are not preferred because they dissolve slowly or are insoluble in water and need to be added at high levels.
[0086] Lubricants : “Lubricants” prevent ingredients from sticking to and clogging tablet punches or capsule filling machines. During tablet production, lubricants also ensure that tablet forming and demolding can be performed with low friction between the solid and the die wall.
[0087] Polyethylene glycol 6000 and sodium benzoate are preferred water soluble and non-hygroscopic binders.In one embodiment, there is provided a compressed solid composition as defined herein, wherein the non-hygroscopic lubricant is selected from: polyethylene glycol 6000 and sodium benzoate.
[0088] Sodium lauryl sulfate imparts a bitter taste and is therefore not preferred.
[0089] Poloxamers and polyethylene glycol 4000 are water soluble but hygroscopic lubricants and are not preferred.In one embodiment, there is provided a compressed solid composition as defined herein, wherein the compressed solid composition does not comprise a hygroscopic lubricant selected from the group consisting of: poloxamers and polyethylene glycol 4000.
[0090] Sodium stearyl fumarate, calcium stearate, colloidal silicon dioxide, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, magnesium stearate, medium chain triglycerides, palmitic acid, stearic acid, talc, zinc stearate are all water-insoluble and therefore are not preferably included in the compressed solid composition as defined herein. In one embodiment, the compressed solid composition does not contain a water-insoluble lubricant selected from the group consisting of sodium stearyl fumarate, calcium stearate, colloidal silicon dioxide, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, magnesium stearate, medium chain triglycerides, palmitic acid, stearic acid, talc and zinc stearate.
[0091] Properties of Compressed Solid Compositions
[0092] According to the present disclosure, there is provided a blend of carefully selected water-soluble excipients that, together with a physiologically acceptable manganese (II) compound and one or more absorption enhancers, allow compression into a solid composition.
[0093] Importantly, multiple tablets produced from a batch by the methods disclosed herein all have substantially the same amounts of ingredients.
[0094] In addition, the compressed solid composition is dissolved in water (such as a glass of water, e.g., about 0.2 L) to provide a clear solution, except for any residual vitamin D that may or may not be present in the compressed solid composition. Vitamin D, when added to water, typically resides on top of the water phase in the form of an oil phase. It is further desirable that the dissolved solid composition has a neutral taste. In one embodiment, the vitamin D is in the form of vitamin D3 100,000. In one embodiment, the vitamin D3 is in the form of dry vitamin D3 100SD / S.
[0095] In one embodiment, the compressed solid composition has sufficient hardness and low moisture content. In one embodiment, the hardness of the compressed solid composition is between 35N and 110N, such as greater than 40N, such as greater than 45N, such as greater than 50N, such as greater than 55N, such as greater than 60N, such as greater than 65N, such as greater than 70N, such as greater than 75N, such as greater than 80N, such as greater than 85N, such as greater than 90N, such as greater than 95N, such as greater than 100N, such as greater than 105N, such as about 110N.
[0096] In one embodiment, the compressed solid composition is used to prepare an oral solution.
[0097] In one embodiment, the compressed solid composition is used as a magnetic resonance imaging (MRI) contrast composition.
[0098] Dissolution rate
[0099] In one embodiment, the compressed solid composition provides a clear solution in water at room temperature in 8 minutes or less, such as in 7 minutes or less, such as in 6 minutes or less, such as in 5 minutes or less, such as in 4 minutes or less, such as in 3 minutes or less, without stirring or agitating the solution. Preferably, the clear solution is formed in 5 minutes, even more preferably in 3 minutes or less.
[0100] In one embodiment, the compressed solid composition provides a clear solution in 0.2L of water at room temperature in 8 minutes or less, such as in 7 minutes or less, such as in 6 minutes or less, such as in 5 minutes or less, such as in 4 minutes or less, such as in 3 minutes or less, without stirring or agitating the solution. Preferably, a clear solution is formed in 5 minutes, even more preferably in 3 minutes or less.
[0101] In one embodiment, the compressed solid composition completely dissolves in water at room temperature in 8 minutes or less, such as in 7 minutes or less, such as in 6 minutes or less, such as in 5 minutes or less, such as in 4 minutes or less, such as in 3 minutes or less, without stirring or agitating the solution. Preferably, the compressed solid composition completely dissolves in water in 5 minutes, even more preferably in 3 minutes or less.
[0102] In one embodiment, the compressed solid composition In 8 minutes Completely dissolved in In cold water (such as between about 2 to about 15° C.). In one embodiment, the compressed solid composition completely dissolves in 0.2 L of water at 5° C. in about 8 minutes.
[0103] Disintegration rate
[0104] In one embodiment, the compressed solid composition disintegrates in water at room temperature in less than 3.0 minutes, such as in less than 2.5 minutes, such as in less than 2 minutes, such as in less than 1.5 minutes, such as in less than 1 minute, without any stirring or agitation of the solution. Preferably, the compressed solid composition disintegrates within 2 minutes, even more preferably within 1 minute or less.
[0105] In one embodiment, the compressed solid composition disintegrates in 0.2 L of water at room temperature in less than 3.0 minutes, such as in less than 2.5 minutes, such as in less than 2 minutes, such as in less than 1.5 minutes, such as in less than 1 minute, without any stirring or agitation of the solution.
[0106] The pH of the resulting solution
[0107] When dispensing effervescent tablets containing manganese into water, it may result in the formation of a precipitate consisting of manganese carbonate salts. These salts can be redissolved by acidifying the resulting solution, preferably by adjusting the pH of the resulting solution to between 2 and 7.
[0108] In one embodiment, the compressed solid composition results in a pH between 2 and 7 in 0.2 L of water after complete dissolution of between 0.5 g and 1 g of manganese(II) chloride tetrahydrate or an equimolar amount of any corresponding manganese(II) salt.
[0109] Physiologically acceptable manganese(II) compounds
[0110] In one embodiment, there is provided a compressed solid composition as defined herein, wherein the physiologically acceptable manganese (II) compound is a salt of an inorganic anion or an organic anion. In one embodiment, the inorganic anion is selected from chloride, fluoride, bromide, iodide, sulfate and phosphate. In one embodiment, the organic anion is selected from ascorbate, kojate, salicylate and gluconate.
[0111] In one embodiment, there is provided a compressed solid composition as defined herein, wherein the physiologically acceptable manganese (II) compound is selected from the group consisting of: manganese (II) sulfate, manganese (II) gluconate, anhydrous manganese (II) chloride, manganese (II) chloride dihydrate, manganese (II) chloride tetrahydrate, and combinations thereof.
[0112] In one embodiment, there is provided a compressed solid composition as defined herein, wherein the physiologically acceptable manganese(II) compound is manganese(II) chloride tetrahydrate.
[0113] In one embodiment, there is provided a compressed solid composition as defined herein, wherein the compressed solid composition comprises between 0.5 g and 1.2 g of manganese(II) chloride tetrahydrate or an equimolar amount of any corresponding manganese(II) salt.
[0114] In one embodiment, there is provided a compressed solid composition as defined herein, wherein the compressed solid composition comprises between 0.6 g and 1 g, such as between 0.65 g and 0.95 g, such as between 0.70 g and 0.90 g, such as between 0.75 g and 0.85 g, such as 0.80 g of manganese (II) chloride tetrahydrate.
[0115] In one embodiment, there is provided a compressed solid composition as defined herein, wherein the compressed solid composition comprises 0.8 g of manganese(II) chloride tetrahydrate or an equimolar amount of any corresponding manganese(II) salt.
[0116] In one embodiment, there is provided a compressed solid composition as defined herein, wherein the compressed solid composition comprises 0.8 g of manganese (II) chloride tetrahydrate or an equimolar amount of the corresponding anhydrate or dihydrate.
[0117] In one embodiment, there is provided a compressed solid composition as defined herein, wherein the composition comprises:
[0118] a) Manganese(II) chloride tetrahydrate or dihydrate;
[0119] b) Alanine, such as L-alanine;
[0120] c) isomalt;
[0121] d) cross-linked carboxymethylcellulose, such as croscarmellose sodium; and
[0122] e) Polyethylene glycol, such as PEG6000.
[0123] In one embodiment, the compressed solid composition further comprises vitamin D, such as vitamin D3.
[0124] Absorption enhancers
[0125] Under physiological conditions, manganese from physiologically acceptable manganese(II) compounds is poorly absorbed from the intestine after oral ingestion, but by using specific absorption enhancers (such as L-alanine and vitamin D3), sufficiently high concentrations can be achieved in the liver to achieve significant signal enhancement effects during MRI.
[0126] The term "absorption enhancer" is used interchangeably herein with the term "uptake enhancer" and refers to a compound capable of enhancing the transport of manganese across the gastrointestinal membrane. These compounds are well known in the art, for example from WO 96 / 05867, and include physiologically tolerated reducing compounds containing an α-hydroxy ketone group, physiologically tolerated acids or salts thereof containing an α- and / or β-hydroxy or amino group, and / or vitamin D.
[0127] In one embodiment, there is provided a compressed solid composition as defined herein, wherein the one or more absorption enhancers are selected from the group consisting of: proteinogenic amino acids and vitamin D.
[0128] In one embodiment, there is provided a compressed solid composition as defined herein, wherein the proteinogenic amino acid is selected from the group consisting of alanine, valine, leucine, tryptophan, methionine, isoleucine, proline, phenylalanine, serine, glycine, threonine, cysteine, asparagine, glutamine, tyrosine, aspartic acid, glutamic acid, arginine, lysine and histidine.
[0129] In one embodiment there is provided a compressed solid composition as defined herein, wherein the proteinogenic amino acid is a neutral amino acid.
[0130] In one embodiment there is provided a compressed solid composition as defined herein, wherein the proteinogenic amino acid is L-alanine.
[0131] In one embodiment, there is provided a compressed solid composition as defined herein, wherein the vitamin D is vitamin D3.
[0132] In one embodiment, there is provided a compressed solid composition as defined herein, comprising two absorption enhancers. In one embodiment, the two absorption enhancers are L-alanine and vitamin D3.
[0133] In one embodiment, a compressed solid composition as defined herein is provided, wherein the compressed solid composition comprises between 0.25g and 0.75g, such as between 0.30g and 0.70g, such as between 0.35g and 0.65g, such as between 0.40g and 0.60g, such as between 0.45g and 0.55g, such as 0.50g of proteinogenic amino acid, such as L-alanine.
[0134] Effervescent composition
[0135] In one embodiment, the compressed solid composition as provided herein is in the form of an effervescent solid composition, such as an effervescent tablet.The effervescent composition as disclosed herein comprises an effervescent couple.
[0136] As used herein, the term "effervescent couple" refers to a pair of pharmaceutically acceptable excipients, one of which is a basic component and the other is an acidic component. The basic component releases carbon dioxide when it comes into contact with the acidic component and water. An example of a basic component is bicarbonate, also known as hydrogen carbonate.
[0137] In one embodiment, the acidic component is citric acid, such as anhydrous citric acid. In one embodiment, the acidic component is malic acid.
[0138] In one embodiment, the alkaline component of the effervescent couple is selected from sodium bicarbonate, anhydrous sodium carbonate and mixtures thereof.
[0139] In one embodiment, the alkaline component is sodium bicarbonate and the acidic component is citric acid, such as citric anhydride.
[0140] In one embodiment, the effervescent tablet has a mass between 1.8 g and 4.0 g, such as between 1.9 g and 3.9 g, such as between 2.0 g and 3.8 g, such as between 2.1 g and 3.7 g, such as between 2.2 g and 3.6 g, such as between 2.3 g and 3.5 g.
[0141] In one embodiment, the compressed solid composition has a mass between 1.8 g and 8.0 g, such as between 1.9 g and 6.0 g, such as between 2.0 g and 4.0 g.
[0142] In one embodiment, the effervescent tablet comprises manganese (II) chloride dihydrate.
[0143] In one embodiment, the compressed solid composition is provided as an effervescent tablet comprising bicarbonate, such as granulated bicarbonate.
[0144] In one embodiment, the effervescent tablet comprises citric acid, such as anhydrous citric acid or citric acid monohydrate.
[0145] In one embodiment, there is provided a compressed solid composition as defined herein, wherein the mass ratio between citric acid and sodium bicarbonate in the effervescent tablet is at least 1.2 to 1, such as at least 1.3 to 1, such as at least 1.4 to 1, such as at least 1.5 to 1, such as at least 1.6 to 1, such as at least 1.7 to 1, such as at least 1.8 to 1, such as at least 1.9 to 1, such as at least 1.9 to 1, such as at least 2.0 to 1, such as at least 2.1 to 1, such as at least 2.2 to 1, such as at least 2.3 to 1, such as at least 2.4 to 1, such as at least 2.5 to 1.
[0146] In one embodiment, the effervescent tablet comprises a sweetener such as isomalt, optionally granulated isomalt. In the context of the present disclosure, isomalt is primarily used as a filler.
[0147] In one embodiment, the effervescent tablet is configured so that after being dispensed into water, the end time of the effervescent period is when the compressed solid composition is completely dissolved. Thus, the end of effervescence can provide an indication of when the oral solution can be used.
[0148] In one embodiment, the compressed solid composition is provided as an effervescent tablet comprising:
[0149] a) Manganese chloride tetrahydrate or dihydrate;
[0150] b) Alanine, such as L-alanine;
[0151] c) isomalt;
[0152] d) bicarbonates, such as sodium bicarbonate;
[0153] e) citric acid, such as citric acid monohydrate; and
[0154] f) Polyethylene glycol, such as polyethylene glycol 6000 (PEG6000).
[0155] In one embodiment, the effervescent tablet further comprises vitamin D, such as vitamin D3.
[0156] In one embodiment, the effervescent tablet is prepared from granules, such as sodium bicarbonate granules.
[0157] In one embodiment, the granules comprise sodium bicarbonate, isomalt and povidone. In one embodiment, the granules comprise 68.7% sodium bicarbonate, 26.7% isomalt and 4.6% povidone by mass.
[0158] In a preferred embodiment, the mass of the effervescent tablet is about 2.5 g, such as 2.44 g.
[0159] In one embodiment, the effervescent tablet comprises:
[0160]
[0161]
[0162] *654.41 mg of manganese chloride dihydrate is equimolar to 800 mg of manganese chloride tetrahydrate.
[0163] In a preferred embodiment, the effervescent tablet comprises:
[0164]
[0165] *654.41 mg of manganese chloride dihydrate is equimolar to 800 mg of manganese chloride tetrahydrate.
[0166] In one embodiment, the composition of vitamin D3 powder 100 000 IU is:
[0167]
[0168] In one embodiment, the effervescent tablet comprises from 480-1120 IU of vitamin D3.
[0169] Package
[0170] Compressed solid compositions as defined herein are preferably packaged using waterproof or moisture-proof materials, such as blisters of suitable waterproof or moisture-proof materials known to those skilled in the art, optionally made of aluminum. Blister packs are preformed packages for solid compositions such as compressed solid compositions provided herein. Blister packs can be used to protect drugs from external factors such as moisture and contamination over long periods of time.
[0171] In one embodiment, a kit is provided, the kit comprising:
[0172] a compressed solid composition as defined herein, and
[0173] Waterproof packaging to protect the compressed solid composition from moisture.
[0174] Preparation of compressed solid compositions
[0175] In one embodiment, there is provided a method for preparing a compressed solid composition as defined herein, wherein the method comprises the following steps:
[0176] a) providing a physiologically acceptable manganese(II) compound, optionally in the form of particles, and optionally drying the physiologically acceptable manganese(II) compound;
[0177] b) providing one or more water-soluble excipients that allow compression;
[0178] c) mixing the physiologically acceptable manganese (II) compound with one or more absorption enhancers and the one or more water-soluble excipients to provide a water-soluble mixture; and
[0179] d) compressing the water soluble mixture to provide a compressed solid composition as defined herein.
[0180] In one embodiment, there is provided a method as defined herein, wherein the relative humidity (rH) is maintained at less than 35%, such as less than 34%, such as less than 33%, such as less than 32%, such as less than 31%, such as less than 30%, such as less than 29%, such as less than 28%, such as less than 27%, such as less than 26%, such as less than 25%, such as less than 24%, such as less than 23%, such as less than 22%, such as less than 21%, such as less than 20%, such as less than 19%, such as less than 18%, such as less than 17%, such as less than 16%, such as less than 15%, such as less than 14%, such as less than 13%, such as less than 12%, such as less than 11%, such as less than 10%.
[0181] In one embodiment, the relative humidity (rH) is maintained below 30%.
[0182] In one embodiment, the relative humidity (rH) is maintained below 25%.
[0183] In one embodiment, the relative humidity (rH) is maintained below 20%.
[0184] In one embodiment there is provided a compressed solid composition as prepared by a process as defined herein.
[0185] project
[0186] I-1. A compressed solid composition comprising: a physiologically acceptable manganese (II) compound, one or more absorption enhancers and one or more water-soluble excipients.
[0187] I-2. The compressed solid composition according to item 1, which is used for preparing an oral solution.
[0188] I-3. The compressed solid composition, which is used as a magnetic resonance imaging (MRI) contrast composition.
[0189] I-4. The compressed solid composition according to any of the preceding items, wherein the one or more water-soluble excipients are non-hygroscopic water-soluble excipients.
[0190] I-5. A compressed solid composition according to any one of the preceding items, wherein the one or more water-soluble excipients are selected from: non-hygroscopic fillers, non-hygroscopic binders, non-hygroscopic disintegrants and non-hygroscopic lubricants.
[0191] I-6. A compressed solid composition according to any one of the preceding items, wherein the non-hygroscopic filler is selected from: isomalt; lactose, such as spray-dried lactose, α-lactose or β-lactose; maltitol; maltose; and mannitol.
[0192] I-7. The compressed solid composition according to any one of the preceding items, wherein the compressed solid composition does not contain a hygroscopic filler selected from the group consisting of dextrose mix, dextrose, fructose, hypromellose, maltodextrin, sucrose, sorbitol and xylitol.
[0193] I-8. A compressed solid composition according to any one of the preceding items, wherein the compressed solid composition does not contain a water-insoluble filler selected from the following: calcium carbonate; calcium phosphate, such as basic calcium phosphate, calcium hydrogen phosphate or dicalcium phosphate; calcium silicate; cellulose powder; cellulose acetate; magnesium carbonate; magnesium oxide; medium chain triglycerides; microcrystalline cellulose; silicified microcrystalline cellulose; polymethacrylate; starch; calcium sulfate; and pregelatinized starch.
[0194] I-9. A compressed solid composition according to any one of the preceding items, wherein the non-hygroscopic binder is selected from the group consisting of: hydroxyethyl methylcellulose, maltose, povidone and dextrin.
[0195] I-10. A compressed solid composition according to any one of the preceding items, wherein the compressed solid composition does not contain a water-insoluble binder selected from the group consisting of gum arabic, hydroxypropyl methylcellulose, methylcellulose, sodium alginate, pregelatinized starch, inulin, agar, gelatin, starch, alginic acid, cellulose acetate phthalate, ethyl cellulose, hydrogenated vegetable oil, magnesium aluminum silicate, microcrystalline cellulose and polymethacrylate.
[0196] I-11. The compressed solid composition according to any of the preceding items, wherein the non-hygroscopic disintegrant is povidone.
[0197] I-12. The compressed solid composition according to any one of the preceding items, further comprising a water-insoluble disintegrant.
[0198] I-13. The compressed solid composition according to any one of the preceding items, wherein the water-insoluble disintegrant is selected from: carboxymethylcellulose calcium; croscarmellose sodium; and crospovidone.
[0199] I-14. The compressed solid composition according to any one of the preceding items, wherein the compressed solid composition does not contain a hygroscopic disintegrant selected from the group consisting of sodium carboxymethylcellulose and hydroxypropylcellulose.
[0200] I-15. The compressed solid composition according to any one of the preceding items, wherein the non-hygroscopic lubricant is selected from: polyethylene glycol 6000 and sodium benzoate.
[0201] I-16. The compressed solid composition according to any of the preceding items, wherein the compressed solid composition does not contain a hygroscopic lubricant selected from the group consisting of poloxamer and polyethylene glycol 4000.
[0202] I-17. A compressed solid composition according to any one of the preceding items, wherein the compressed solid composition does not contain a water-insoluble lubricant selected from the following: sodium stearyl fumarate, calcium stearate, colloidal silicon dioxide, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, magnesium stearate, medium chain triglycerides, palmitic acid, stearic acid, talc and zinc stearate.
[0203] I-18. The compressed solid composition according to any of the preceding items, wherein the physiologically acceptable manganese(II) compound is a salt of an inorganic anion or an organic anion.
[0204] I-19. A compressed solid composition according to any one of the preceding items, wherein the inorganic anion is selected from chloride, fluoride, bromide, iodide, sulfate and phosphate.
[0205] I-20. The compressed solid composition according to any one of the preceding items, wherein the organic anion is selected from the group consisting of ascorbate, kojic acid, salicylate and gluconate.
[0206] I-21. A compressed solid composition according to any of the preceding items, wherein the physiologically acceptable manganese (II) compound is selected from: manganese (II) sulfate, manganese (II) gluconate, anhydrous manganese (II) chloride, manganese (II) chloride dihydrate, manganese (II) chloride tetrahydrate and combinations thereof.
[0207] I-22. The compressed solid composition according to any of the preceding items, wherein the physiologically acceptable manganese(II) compound is manganese(II) chloride tetrahydrate.
[0208] I-23. A compressed solid composition according to any of the preceding items, wherein the one or more absorption enhancers are selected from: protein amino acids and vitamin D.
[0209] I-24. A compressed solid composition according to any one of the preceding items, wherein the proteinogenic amino acids are selected from alanine, valine, leucine, tryptophan, methionine, isoleucine, proline, phenylalanine, serine, glycine, threonine, cysteine, asparagine, glutamine, tyrosine, aspartic acid, glutamic acid, arginine, lysine and histidine.
[0210] I-25. A compressed solid composition according to any one of the preceding items, wherein the proteinogenic amino acid is a neutral amino acid.
[0211] I-26. A compressed solid composition according to any one of the preceding items, wherein the proteinogenic amino acid is L-alanine.
[0212] I-27. A compressed solid composition according to any of the preceding items, wherein the vitamin D is vitamin D3.
[0213] I-28. The compressed solid composition according to any one of the preceding items, comprising two absorption enhancers.
[0214] I-29. A compressed solid composition according to any one of the preceding items, wherein the two absorption enhancers are L-alanine and vitamin D3.
[0215] I-30. A compressed solid composition according to any of the preceding items, wherein the compressed solid composition comprises between 0.5 g and 1.2 g of manganese(II) chloride tetrahydrate or an equimolar amount of any corresponding manganese(II) salt.
[0216] I-31. A compressed solid composition according to any of the preceding items, wherein the compressed solid composition contains between 0.6g and 1g, such as between 0.65g and 0.95g, such as between 0.70g and 0.90g, such as between 0.75g and 0.85g, such as 0.80g of manganese (II) chloride tetrahydrate.
[0217] I-32. A compressed solid composition according to any one of the preceding items, wherein the compressed solid composition comprises 0.8 g of manganese(II) chloride tetrahydrate or an equimolar amount of any corresponding manganese(II) salt.
[0218] I-33. A compressed solid composition according to any one of the preceding items, wherein the compressed solid composition comprises 0.8 g of manganese (II) chloride tetrahydrate or an equimolar amount of the corresponding anhydrate or dihydrate.
[0219] I-34. A compressed solid composition according to any of the preceding items, wherein the compressed solid composition contains between 0.25g and 0.75g, such as between 0.30g and 0.70g, such as between 0.35g and 0.65g, such as between 0.40g and 0.60g, such as between 0.45g and 0.55g, such as 0.50g of L-alanine.
[0220] I-35. A compressed solid composition according to any of the preceding items, wherein the compressed solid composition provides a clear solution in water at room temperature within 8 minutes or less, such as within 7 minutes or less, such as within 6 minutes or less, such as within 5 minutes or less, such as within 4 minutes or less, such as within 3 minutes or less, without stirring or agitating the solution.
[0221] I-36. A compressed solid composition according to any of the preceding items, wherein the compressed solid composition provides a clear solution in 0.2 L of water at room temperature within 8 minutes or less, such as within 7 minutes or less, such as within 6 minutes or less, such as within 5 minutes or less, such as within 4 minutes or less, such as within 3 minutes or less, without stirring or agitating the solution.
[0222] I-37. A compressed solid composition according to any of the preceding items, wherein the compressed solid composition completely dissolves in water at room temperature in 8 minutes or less, such as in 7 minutes or less, such as in 6 minutes or less, such as in 5 minutes or less, such as in 4 minutes or less, such as in 3 minutes or less, without stirring or agitating the solution. I-38. A compressed solid composition according to any of the preceding items, wherein the compressed solid composition disintegrates in water at room temperature in less than 3.0 minutes, such as in less than 2.5 minutes, such as in less than 2 minutes, such as in less than 1.5 minutes, such as in less than 1 minute, without any stirring or agitation of the solution.
[0223] I-39. A compressed solid composition according to any of the preceding items, wherein the compressed solid composition disintegrates in 0.2 L of water at room temperature in less than 3.0 minutes, such as in less than 2.5 minutes, such as in less than 2 minutes, such as in less than 1.5 minutes, such as in less than 1 minute, without any stirring or agitation of the solution.
[0224] I-40. A compressed solid composition according to any of the preceding items, wherein after complete dissolution of between 0.5 g and 1 g of manganese(II) chloride tetrahydrate or an equimolar amount of any corresponding manganese(II) salt, the compressed solid composition results in a pH between 2 and 7 in 0.2 L of water.
[0225] I-41. The compressed solid composition according to any of the preceding items, wherein the compressed solid composition is an effervescent composition.
[0226] I-42. A compressed solid composition according to any of the preceding items, wherein the effervescent tablet has a mass between 1.8g and 4.0g, such as between 1.9g and 3.9g, such as between 2.0g and 3.8g, such as between 2.1g and 3.7g, such as between 2.2g and 3.6g, such as between 2.3g and 3.5g.
[0227] I-43. The compressed solid composition according to any one of the preceding items, wherein the effervescent tablet comprises manganese (II) chloride dihydrate.
[0228] I-44. A compressed solid composition according to any one of the preceding items, wherein the effervescent tablet comprises bicarbonate, such as granular bicarbonate.
[0229] I-45. A compressed solid composition according to any one of the preceding items, wherein the effervescent tablet comprises citric acid, such as anhydrous citric acid or citric acid monohydrate.
[0230] I-46. A compressed solid composition according to any of the preceding items, wherein the mass ratio between citric acid and sodium bicarbonate in the effervescent tablet is at least 1.2 to 1, such as at least 1.3 to 1, such as at least 1.4 to 1, such as at least 1.5 to 1, such as at least 1.6 to 1, such as at least 1.7 to 1, such as at least 1.8 to 1, such as at least 1.9 to 1, such as at least 1.9 to 1, such as at least 2.0 to 1, such as at least 2.1 to 1, such as at least 2.2 to 1, such as at least 2.3 to 1, such as at least 2.4 to 1, such as at least 2.5 to 1.
[0231] I-47. A compressed solid composition according to any one of the preceding items, wherein the effervescent tablet comprises:
[0232] a. Manganese chloride tetrahydrate, dihydrate or anhydrous;
[0233] b. Alanine;
[0234] c. Isomalt;
[0235] d. bicarbonates, such as sodium bicarbonate;
[0236] e. citric acid, such as citric acid monohydrate; and
[0237] f. Polyethylene glycol, such as polyethylene glycol 6000 (PEG6000).
[0238] I-48. A compressed solid composition according to item 47, further comprising vitamin D3.
[0239] I-49. A compressed solid composition according to any one of the preceding items, wherein the composition comprises:
[0240] a. Manganese(II) chloride tetrahydrate, dihydrate or anhydrous;
[0241] b. Alanine;
[0242] c. Isomalt;
[0243] d. cross-linked carboxymethyl cellulose, such as cross-linked carboxymethyl cellulose sodium; and
[0244] e. Polyethylene glycol, such as PEG6000.
[0245] I-50. A compressed solid composition according to item 49, further comprising vitamin D3.
[0246] I-51. A kit of parts, comprising:
[0247] a) a compressed solid composition according to any one of the preceding items; and
[0248] b) Waterproof packaging.
[0249] I-52. A method for preparing a compressed solid composition according to any one of the preceding items, wherein the method comprises the following steps:
[0250] a. providing a physiologically acceptable manganese (II) compound, optionally in the form of particles, and optionally drying the physiologically acceptable manganese (II) compound;
[0251] b. providing one or more absorption enhancers;
[0252] c. providing one or more water-soluble excipients that allow compression;
[0253] d. mixing the physiologically acceptable manganese (II) compound with the one or more absorption enhancers and the one or more water-soluble excipients to provide a water-soluble mixture; and
[0254] e. Compressing the water-soluble mixture to provide a compressed solid composition according to any one of the preceding items.
[0255] I-53. A method according to any of the preceding items, wherein the relative humidity (RH) is maintained at less than 35%, such as less than 34%, such as less than 33%, such as less than 32%, such as less than 31%, such as less than 30%, such as less than 29%, such as less than 28%, such as less than 27%, such as less than 26%, such as less than 25%, such as less than 24%, such as less than 23%, such as less than 22%, such as less than 21%, such as less than 20%, such as less than 19%, such as less than 18%, such as less than 17%, such as less than 16%, such as less than 15%, such as less than 14%, such as less than 13%, such as less than 12%, such as less than 11%, such as less than 10%.
[0256] I-54. A compressed solid composition prepared by the method according to any one of the preceding items.
[0257] I-55. A method for preparing an oral MRI solution, the method comprising:
[0258] a. Providing a compressed solid composition according to any one of the preceding items; and
[0259] b. Provide adequate water, and
[0260] c. adding the compressed solid composition to the water,
[0261] Thereby forming the oral MRI solution.
[0262] Project II
[0263] 1. A compressed solid composition comprising: a physiologically acceptable manganese (II) compound, one or more absorption enhancers and one or more water-soluble excipients, optionally wherein the compressed solid composition is used to prepare an oral solution such as for use in magnetic resonance imaging (MRI).
[0264] 2. The compressed solid composition according to item 1, wherein the one or more water-soluble excipients are selected from: non-hygroscopic fillers, non-hygroscopic binders, non-hygroscopic disintegrants and non-hygroscopic lubricants.
[0265] 3. A compressed solid composition according to any one of the preceding items, wherein the non-hygroscopic filler is selected from: isomalt; lactose, such as spray-dried lactose, α-lactose or β-lactose; maltitol; maltose; and mannitol.
[0266] 4. A compressed solid composition according to any one of the preceding items, wherein the non-hygroscopic binder is selected from the group consisting of hydroxyethyl methylcellulose, maltose, povidone and dextrin.
[0267] 5. The compressed solid composition according to any one of the preceding items, wherein the non-hygroscopic disintegrant is povidone.
[0268] 6. The compressed solid composition according to any one of the preceding items, wherein the non-hygroscopic lubricant is selected from: polyethylene glycol 6000 and sodium benzoate.
[0269] 7. A compressed solid composition according to any one of the preceding items, wherein the physiologically acceptable manganese (II) compound is selected from: manganese (II) sulfate, manganese (II) gluconate, anhydrous manganese (II) chloride, manganese (II) chloride dihydrate, manganese (II) chloride tetrahydrate and combinations thereof.
[0270] 8. A compressed solid composition according to any one of the preceding items, wherein the one or more absorption enhancers are selected from: protein amino acids and vitamin D, optionally wherein the compressed solid composition comprises two absorption enhancers, such as L-alanine and vitamin D3.
[0271] 9. A compressed solid composition according to any one of the preceding items, wherein the compressed solid composition comprises between 0.5 g and 1.2 g of manganese(II) chloride tetrahydrate or an equimolar amount of any corresponding manganese(II) salt.
[0272] 10. A compressed solid composition according to any of the preceding items, wherein the compressed solid composition provides a clear solution in water (such as 0.2 L) and / or completely dissolves therein in 8 minutes or less, such as in 7 minutes or less, such as in 6 minutes or less, such as in 5 minutes or less, such as in 4 minutes or less, such as in 3 minutes or less at room temperature without stirring or agitating the solution.
[0273] 11. A compressed solid composition according to any of the preceding items, wherein after complete dissolution of between 0.5 g and 1 g of manganese(II) chloride tetrahydrate or an equimolar amount of any corresponding manganese(II) salt, the compressed solid composition results in a pH between 2 and 7 in 0.2 L of water.
[0274] 12. The compressed solid composition according to any one of the preceding items, wherein the compressed solid composition is an effervescent composition.
[0275] 13. A method for preparing a compressed solid composition according to any one of the preceding items, wherein the method comprises the following steps:
[0276] a. providing a physiologically acceptable manganese (II) compound, optionally in the form of particles, and optionally drying the physiologically acceptable manganese (II) compound;
[0277] b. providing one or more absorption enhancers;
[0278] c. providing one or more water-soluble excipients that allow compression;
[0279] d. mixing the physiologically acceptable manganese (II) compound with the one or more absorption enhancers and the one or more water-soluble excipients to provide a water-soluble mixture; and
[0280] e. Compressing the water soluble mixture to provide a composition according to any one of the preceding items.
[0281] 14. The method according to any one of the preceding items, wherein the relative humidity (RH) is maintained at less than 35%, such as less than 34%, such as less than 33%, such as less than 32%, such as less than 31%, such as less than 30%, such as less than 29%, such as less than 28%, such as less than 27%, such as less than 26%, such as less than 25%, such as less than 24%, such as less than 23%, such as less than 22%, such as less than 21%, such as less than 20%, such as less than 19%, such as less than 18%, such as less than 17%, such as less than 16%, such as less than 15%, such as less than 14%, such as less than 13%, such as less than 12%, such as less than 11%, such as less than 10%.
[0282] 15. A method for preparing an oral MRI solution, the method comprising:
[0283] a. Providing a compressed solid composition according to any one of the preceding items; and
[0284] b. Provide adequate water, and
[0285] c. adding the compressed solid composition to the water,
[0286] Thereby forming the oral MRI solution.
[0287] Project III
[0288] 1. An effervescent MRI tablet for magnetic resonance imaging (MRI), the tablet comprising:
[0289] a) manganese(II) chloride tetrahydrate in the range of 0.50 g to 1.2 g or an equimolar amount of the corresponding anhydrate or dihydrate;
[0290] b) L-alanine in the range of 0.25 g to 0.75 g;
[0291] c) one or more water-soluble excipients; and
[0292] d) an effervescent couple, the effervescent couple comprising an alkaline component and an acidic component;
[0293] The effervescent tablet is used for preparing an oral solution for MRI.
[0294] 2. The effervescent MRI tablet according to item 1, wherein the one or more water-soluble excipients are selected from: non-hygroscopic fillers, non-hygroscopic binders, non-hygroscopic disintegrants, non-hygroscopic lubricants and combinations thereof.
[0295] 3. The effervescent MRI sheet according to item 2, comprising the non-hygroscopic filler, wherein the non-hygroscopic filler is selected from the group consisting of: isomalt; lactose; maltitol; maltose; and mannitol.
[0296] 4. The effervescent MRI sheet according to item 2, comprising the non-hygroscopic binder, wherein the non-hygroscopic binder is selected from the group consisting of: hydroxyethyl methylcellulose; maltose; povidone; and dextrin.
[0297] 5. The effervescent MRI tablet according to item 2, comprising the non-hygroscopic disintegrant povidone.
[0298] 6. The effervescent MRI sheet according to item 2, comprising the non-hygroscopic lubricant, wherein the non-hygroscopic lubricant is selected from: polyethylene glycol 6000; and sodium benzoate.
[0299] 7. The effervescent MRI tablet according to item 1, wherein the effervescent MRI tablet further comprises vitamin D3.
[0300] 8. The effervescent MRI tablet according to item 1, wherein the effervescent MRI tablet comprises 0.50 g of L-alanine.
[0301] 9. The effervescent MRI tablet according to item 1, wherein the effervescent MRI tablet provides a clear solution in 0.2 L of water at room temperature in 5 minutes or less without stirring or agitating the solution.
[0302] 10. The effervescent MRI tablet according to item 1, wherein the effervescent MRI tablet completely dissolves in water at room temperature within 5 minutes without stirring or agitating the solution.
[0303] 11. The effervescent MRI tablet according to item 1, wherein the effervescent MRI tablet disintegrates in less than 3.0 minutes in 0.2 L of water at room temperature without any stirring or agitation of the solution.
[0304] 12. The effervescent MRI tablet according to item 1, wherein after between 0.5 g and 1 g of manganese (II) chloride tetrahydrate or an equimolar amount of the corresponding anhydrate or dihydrate is completely dissolved, the effervescent MRI tablet results in a pH between 2 and 7 in 0.2 L of water.
[0305] 13. The effervescent MRI tablet according to item 1, wherein the effervescent MRI tablet has a mass ranging from 1.8 g to 4.0 g.
[0306] 14. The effervescent MRI tablet according to item 1, wherein the effervescent MRI tablet comprises granular bicarbonate.
[0307] 15. The effervescent MRI tablet according to item 1, wherein the effervescent MRI tablet comprises citric acid.
[0308] 16. The effervescent MRI tablet according to item 1, comprising citric acid and sodium bicarbonate, wherein the mass ratio between the citric acid and the sodium bicarbonate in the effervescent MRI tablet is 1.2 to 1.
[0309] 17. The effervescent MRI tablet according to item 1, wherein the effervescent MRI tablet comprises:
[0310] a. Manganese chloride tetrahydrate, dihydrate or anhydrous;
[0311] bL-alanine;
[0312] c. Isomalt;
[0313] d. Sodium bicarbonate;
[0314] e. citric acid; and
[0315] f.PEG6000.
[0316] 18. The effervescent MRI tablet according to item 1, wherein the effervescent MRI tablet consists of:
[0317] a. Manganese chloride tetrahydrate, dihydrate or anhydrous;
[0318] bL-alanine;
[0319] c. Isomalt;
[0320] d. Sodium bicarbonate;
[0321] e. citric acid;
[0322] f.PEG6000;
[0323] g. povidone; and
[0324] h. Vitamin D3.
[0325] 19. A method for preparing the effervescent MRI tablet according to item 1, wherein the method comprises the following steps:
[0326] a) providing a physiologically acceptable manganese (II) compound;
[0327] b) providing one or more absorption enhancers;
[0328] c) providing one or more water-soluble excipients that allow compression;
[0329] d) mixing the physiologically acceptable manganese (II) compound with the one or more absorption enhancers and the one or more water-soluble excipients to provide a water-soluble mixture; and
[0330] e) compressing the water soluble mixture to provide an effervescent MRI tablet;
[0331] Therein the relative humidity (RH) was maintained below 30%.
[0332] 20. A method for preparing an oral MRI solution, the method comprising:
[0333] a. Providing the effervescent MRI tablet according to item 1,
[0334] b. Provide adequate water, and
[0335] c. adding the effervescent MRI tablet to the water,
[0336] d. thereby forming the oral MRI solution.
[0337] Example
[0338] In the following examples, Examples 1 to 9 relate to non-effervescent tablets, referred to herein as "soluble tablets", and Examples 10 to 18 relate to effervescent tablets, referred to herein as "effervescent tablets".
[0339] • Examples 1-3 are examples of formulations that produce clear solutions within 5 minutes after introduction into water.
[0340] • Examples 4 and 7-8 illustrate the problems associated with high air humidity.
[0341] Example 5 illustrates the problem that drying the manganese chloride prior to mixing can lead to high hygroscopicity.
[0342] • Examples 6 and 9 are examples of compositions that fail to produce a clear solution upon introduction into water.
[0343] • Examples 10-12 illustrate the preparation of effervescent tablets that produce good performance at low relative humidity.
[0344] • Examples 13-14 illustrate how effervescent tablets prepared at higher relative humidity perform poorly.
[0345] • Example 11 and Examples 15-18 illustrate the effect of drying the manganese chloride directly or during the granulation process.
[0346] • Examples 16-18 illustrate the effect of granulation of tablet ingredients on modifying the dissolution profile.
[0347] Example 1: Soluble tablet based on isomalt, tablet weight 2000 mg
[0348] Manganese chloride tetrahydrate, alanine, isomalt, croscarmellose sodium and PEG6000 were mixed for 5 minutes, wherein the relative humidity (rH) in the air was 24% rH. The tablets were compressed on a single punch tablet press using a 20 mm flat tool, wherein the tablet weight was 2000 mg and the hardness was 40 N. The content of manganese chloride tetrahydrate was 800 mg / tablet and the content of alanine was 500 mg / tablet. One tablet was placed in a glass containing 200 ml of water at room temperature, and the tablet disintegrated within one minute and rapidly dissolved completely within three minutes to obtain a clear solution.
[0349] in conclusion
[0350] Under conditions where the relative humidity in the air is low, tablets can be produced according to the above method and will rapidly disintegrate and dissolve to form a clear solution with a neutral taste.
[0351] Example 2: Soluble tablet based on isomalt, tablet weight 2500 mg
[0352] Manganese chloride tetrahydrate, alanine, isomalt, croscarmellose sodium and PEG6000 were mixed for 5 minutes. The tablets were compressed on a single punch tablet press using a 20 mm flat tool, with a tablet weight of 2500 mg and a hardness of 90 N. The content of manganese chloride tetrahydrate was 800 mg / tablet and the content of alanine was 500 mg / tablet. One tablet was placed in a glass containing 200 ml of water at room temperature, and the tablet disintegrated within three minutes and was completely dissolved within five minutes to obtain a clear solution.
[0353] Example 3: Soluble tablets based on isomalt, weighing 2000 mg, with added vitamin D
[0354] Manganese chloride tetrahydrate, alanine, dry vitamin D3 100SD / S, isomalt, cross-linked sodium carboxymethylcellulose and PEG6000 were mixed for 5 minutes. The tablets were compressed on a single punch tablet press using a 20 mm flat tool, where the tablet weight was 2000 mg. The content of manganese chloride tetrahydrate was 800 mg / tablet, the content of alanine was 500 mg / tablet, and the content of vitamin D was 20 μg / tablet plus 20% excess. One tablet was placed in a glass with 200 ml of water at room temperature, and the tablet completely dissolved within five minutes to obtain a clear solution with a little shadow from vitamin D on the top.
[0355] Example 4: Water adsorption of a soluble tablet based on isomalt with a tablet weight of 2000 mg and added vitamin D at 35% rH
[0356] Manganese chloride tetrahydrate, alanine, dry vitamin D3 100SD / S, isomalt, croscarmellose sodium and PEG6000 were mixed for 5 minutes, wherein the relative humidity in the air was 35% rH. The tablets were compressed on a single punch tablet press using a 20 mm flat tool, wherein the tablet weight was 2000 mg and the hardness was 85 N. During processing, the granules adsorbed moisture from the air, formed lumps and did not feed well on the tablet press. The content of manganese chloride tetrahydrate was 800 mg / tablet, the content of alanine was 500 mg / tablet, and the content of vitamin D was 20 μg / tablet plus 20% excess. One tablet was placed in a glass with 200 ml of water at room temperature, and the tablet disintegrated within four minutes and dissolved completely within nine minutes to give a clear solution.
[0357] in conclusion
[0358] The air humidity in the production area needs to be kept low, such as below 25% rH, otherwise the mix will absorb moisture and form lumps, and the tablet dissolution time will increase.
[0359] Example 5: Soluble tablets based on isomalt, wherein manganese chloride is dry Manganese chloride tetrahydrate was dried at 100°C overnight until constant weight. The weight loss was about 22%. Dry manganese chloride, alanine, dry vitamin D3100SD / S, isomalt, croscarmellose sodium and PEG6000 were mixed for 5 minutes, wherein the relative humidity in the air was 17% rH. The tablets were compressed on a single punch tablet press using a 20 mm flat tool, wherein the tablet weight was 2000 mg and the hardness was 61 N. The content of manganese chloride tetrahydrate was 800 mg / tablet, the content of alanine was 500 mg / tablet, and the content of vitamin D was 20 μg / tablet plus 20% excess. One tablet was placed in a glass with 200 ml of water at room temperature, and the tablet did not disintegrate but slowly dissolved from the surface. The tablet was completely dissolved within eight minutes, resulting in a clear solution with a little shadow from the vitamin D on the top.
[0360] in conclusion
[0361] This example illustrates that drying manganese chloride tetrahydrate makes it very hygroscopic and it absorbs moisture from the disintegrant, rendering the disintegrant ineffective. However, the tablets were still able to dissolve to give a clear solution, except for the oily vitamin D3 on top.
[0362]
[0363]
[0364] Table 1 : Batch compositions of Examples 1 to 5, in grams.
[0365] Example 6: Soluble tablet based on isomalt, weighing 2000 mg, but containing a water-insoluble disintegrant
[0366] Manganese chloride tetrahydrate, alanine, isomalt, crospovidone and PEG6000 were mixed for 5 minutes, wherein the relative humidity in the air was 24% rH. The tablets were compressed on a single punch tablet press using a 20 mm flat tool, wherein the tablet weight was 2000 mg and the hardness was 40 N. The content of manganese chloride tetrahydrate was 800 mg / tablet and the content of alanine was 500 mg / tablet. One tablet was placed in a glass containing 200 ml of water at room temperature, and the tablet disintegrated within one minute and rapidly dissolved completely within three minutes to obtain a clear solution in which the crospovidone particles were not dissolved.
[0367] in conclusion
[0368] Based on this example, it appears that the use of water insoluble disintegrants, such as crospovidone, does not provide clear solutions, even at low levels of disintegrant.
[0369] Example 7: Mannitol-based soluble tablets at high humidity
[0370] Manganese chloride tetrahydrate, alanine, mannitol, crospovidone and PEG6000 were mixed for 5 minutes, wherein the relative humidity in the air was 45% rH. The tablets were compressed on a single punch tablet press using a 12 mm flat tool, wherein the tablet weight was 666. During processing, the particles adsorbed moisture from the air, resulting in severe adhesion to the punch and die. The content of manganese chloride tetrahydrate was 800 mg / 3 tablets, and the content of alanine was 500 mg / 3 tablets. Three tablets were placed in a glass containing 200 ml of water at room temperature, and the tablets were completely dissolved within five minutes to obtain a clear solution with a sweet taste.
[0371] in conclusion
[0372] The air humidity in the production area needs to be kept low, such as below 25% rH, otherwise the mixture will absorb moisture and form lumps, which will render the tableting process ineffective and introduce uncertainty into the final dose in the tablet.
[0373] Example 8: Maltitol-based soluble tablets at high humidity
[0374] Manganese chloride tetrahydrate, alanine, maltitol, crospovidone and PEG6000 were mixed for 5 minutes, wherein the relative humidity in the air was 45% rH. The tablets were compressed on a single punch tablet press using a 12 mm flat tool, wherein the tablet weight was 666. During processing, the granules absorbed moisture from the air, formed lumps and did not feed well on the tablet press. The content of manganese chloride tetrahydrate was 800 mg / 3 tablets, and the content of alanine was 500 mg / 3 tablets. Three tablets were placed in a glass with 200 ml of water at room temperature, and the tablets were completely dissolved within seven minutes to obtain a clear solution with a bitter taste.
[0375] in conclusion
[0376] The air humidity in the production area needs to be kept low, such as below 25% rH, to prevent the admixture from absorbing moisture.
[0377] Example 6 Example 7 Example 8 Example 9 Manganese chloride tetrahydrate 20.0 8.0 8.0 20.0 Alanine 12.5 5.0 5.0 12.5 Isomalt 14.25 - - 14.13 Mannitol - 6.5 - - Maltitol - - 6.5 - Croscarmellose Sodium - 0.1 0.1 - Crospovidone 0.25 - - 0.25 PEG6000 3.0 0.4 0.4 3.0 Magnesium Stearate - - - 0.13 total 50.0 20.0 20.0 50.0
[0378] Table 2: Batch compositions of Examples 6 to 9, in grams.
[0379] Example 9: Soluble tablet based on isomalt, weighing 2000 mg, but containing a water-insoluble lubricant
[0380] Manganese chloride tetrahydrate, alanine, isomalt, croscarmellose sodium and PEG6000 were mixed for 5 minutes, wherein the relative humidity in the air was 23% rH. Magnesium stearate was added and mixed for 1 minute. The tablets were compressed on a single punch tablet press using a 20 mm flat tool, wherein the tablet weight was 2000 mg and the hardness was 88 N. The content of manganese chloride tetrahydrate was 800 mg / tablet and the content of alanine was 500 mg / tablet. One tablet was placed in a glass cup containing 200 ml of water at room temperature, and the tablet disintegrated within four minutes and was completely dissolved within seven minutes.
[0381] in conclusion
[0382] This example illustrates that a water insoluble lubricant such as magnesium stearate provides a tablet that upon addition to water gives an unclear, grayish, milky solution with foam on top.
[0383] Example 10: Effervescent tablets containing a small amount of isomalt perform well
[0384] Manganese chloride tetrahydrate, alanine, isomalt, sodium bicarbonate, anhydrous citric acid and PEG6000 were mixed for 5 minutes, wherein the relative humidity in the air was 24% rH. The tablets were compressed on a single punch tablet press using a 20 mm flat tool, wherein the tablet weight was 2565 mg and the hardness was 56 N. The content of manganese chloride tetrahydrate was 800 mg / tablet and the content of alanine was 500 mg / tablet. One tablet was placed in a glass cup with 200 ml of water at room temperature, and the tablet effervescent for about 3.5 minutes. Since manganese ions form a precipitate with carbonate ions, a precipitate of manganese carbonate is formed. At acidic pH, this precipitate can be redissolved, and redissolution is achieved after 4.5 minutes to obtain a clear solution with a slightly sour taste.
[0385] in conclusion
[0386] This example demonstrates that under conditions of low relative humidity in the air (such as 24% rH) it is possible to produce tablets that will rapidly disintegrate and dissolve in water to provide a clear solution with an acceptable taste.
[0387] Example 11: Effervescent tablets containing more isomalt perform well
[0388] Manganese chloride tetrahydrate, alanine, isomalt, sodium bicarbonate, anhydrous citric acid and PEG6000 are mixed for 5 minutes, wherein the relative humidity in the air is 24% rH. The tablets are compressed on a single punch tablet press using a 20 mm flat tool, wherein the tablet weight is 2990 mg and the hardness is 90 N. The content of manganese chloride tetrahydrate is 800 mg / tablet and the content of alanine is 500 mg / tablet. A tablet is placed in a glass cup equipped with 200 ml of water at room temperature, and the tablet effervesces for about 3 minutes. A manganese carbonate precipitate is formed, and it redissolves after 5 minutes to obtain a slightly sour clear solution.
[0389] in conclusion
[0390] This example demonstrates that under conditions of low relative humidity in the air, such as 24% rH, tablets can be produced that rapidly disintegrate and dissolve to provide a clear solution with an acceptable taste.
[0391] Example 12: Effervescent tablet with dried manganese chloride
[0392] Manganese chloride tetrahydrate was dried overnight at 100°C until constant weight. About 22% of weight was lost. Dried manganese chloride tetrahydrate, alanine, isomalt, sodium bicarbonate, anhydrous citric acid and PEG6000 were mixed for 5 minutes, wherein the relative humidity in the air was 35% rH. The tablets were compressed on a single punch tablet press using a 20 mm flat tool, wherein the tablet weight was 2420 mg and the hardness was 55 N. Adhesion occurred when the mixture absorbed moisture from the air. The content of manganese chloride tetrahydrate was 800 mg / tablet and the content of alanine was 500 mg / tablet. A tablet was placed in a glass cup containing 200 ml of water at room temperature, and the tablet effervescent for about 3 minutes. A manganese carbonate precipitate was formed, and it redissolved after 3.5 minutes to obtain a slightly sour clear solution.
[0393] in conclusion
[0394] This example illustrates that drying manganese chloride tetrahydrate makes it very hygroscopic. Hygroscopic manganese chloride absorbs moisture from the air, causing problems during tableting, but the tablets still go into solution quickly.
[0395] Example 13: Effervescent tablet with high level of "effervescent mixture" at high humidity
[0396] Manganese chloride tetrahydrate, alanine, sodium bicarbonate, anhydrous citric acid and PEG6000 are mixed for 5 minutes, wherein the relative humidity in the air is 44% rH. The tablets are compressed on a single punch tablet press using a 12 mm flat tool, wherein the tablet weight is approximately 867 mg. During the compression process, the mixture absorbs moisture, and adhesion is found after compressing several tablets. The content of manganese chloride tetrahydrate is 800 mg / 3 tablets, and the content of alanine is 500 mg / 3 tablets. Three tablets are distributed in a glass cup equipped with 200 ml of water at room temperature, and the tablets effervesce for about 2 minutes. A manganese carbonate precipitate is formed, and it redissolves after 5 minutes to obtain a slightly sour clear solution.
[0397] in conclusion
[0398] This example illustrates that the relative humidity of the air in the production area must be kept low to ensure an efficient tableting process. Producing tablets at 44% rH resulted in the mix absorbing moisture and sticking during compression.
[0399] Example 14: Effervescent tablet with low level of "effervescent mixture" under high humidity
[0400] Manganese chloride tetrahydrate, alanine, sodium bicarbonate, anhydrous citric acid and PEG6000 were mixed for 5 minutes, wherein the relative humidity in the air was 52% rH. The tablets were compressed on a single punch tablet press using a 12 mm flat tool, wherein the tablet weight was approximately 692 mg. During the compression process, the mixture absorbed moisture and severe adhesion occurred. The content of manganese chloride tetrahydrate was 800 mg / 3 tablets, and the content of alanine was 500 mg / 3 tablets. Three tablets were placed in a glass cup containing 200 ml of water at room temperature, and the tablets effervescent for approximately 3 minutes. A manganese carbonate precipitate was formed, and it redissolved after 5 minutes to obtain a slightly sour clear solution.
[0401] in conclusion
[0402] This example illustrates that the relative humidity of the air in the production area must be kept low to ensure an efficient tableting process. Producing tablets at 52% rH resulted in the blend absorbing moisture during compression and severe sticking.
[0403]
[0404] Table 3: Batch compositions of Examples 10 to 14, in grams.
[0405] Example 15: Effervescent tablet granulated with manganese chloride / citric acid
[0406] 28.1 g of manganese chloride tetrahydrate, 21.1 g of citric acid monohydrate and 0.9 g of povidone were mixed in a high shear mixer. Ethanol 96% was added as a granulation aid while stirring until the powder was fully wetted (5.3 g). The granules were dried at 100° C. overnight until constant weight and sieved through a mesh 710 μm.
[0407] Manganese chloride / citric acid granules, alanine, isomalt, sodium bicarbonate and PEG6000 were mixed for 5 minutes, wherein the relative humidity in the air was 24% rH. The tablets were compressed on a single punch tablet press using a 20 mm flat tool, wherein the tablet weight was 2395 mg and the hardness was 70 N. The content of manganese chloride tetrahydrate was 800 mg / tablet, the content of alanine was 500 mg / tablet and the content of anhydrous citric acid was 600 mg / tablet. A tablet was placed in a glass cup containing 200 ml of water at room temperature, and the tablet effervescent for about 3 minutes. A manganese carbonate precipitate was formed (less than in the previous example), and it redissolved after 4 minutes to obtain a slightly sour clear solution.
[0408] in conclusion
[0409] This example illustrates that manganese chloride / citric acid granulation can be beneficial because it reduces the amount of precipitate formed and provides a rapid tablet dissolution time.
[0410] Example 16: Effervescent Tablet Granulated with Sodium Bicarbonate
[0411] Manganese chloride tetrahydrate was dried overnight at 100°C until constant weight. About 22% weight loss. 68.74 g sodium bicarbonate, 26.7 g isomalt and 4.58 g povidone were mixed in a high shear mixer. Ethanol 96% was added as a granulation aid while stirring until the powder was fully wetted (19.7 g). The granules were dried overnight at 100°C and sieved through a sieve 710 μm.
[0412] Dried manganese chloride tetrahydrate, alanine, sodium bicarbonate granules, anhydrous citric acid and PEG6000 were mixed for 5 minutes for granulation, wherein the relative humidity in the air was 24% rH. The tablets were compressed on a single punch tablet press using a 20 mm flat tool, wherein the tablet weight was 2445 mg and the hardness was 68 N. The content of manganese chloride tetrahydrate was 800 mg / tablet, the content of alanine was 500 mg / tablet and the content of sodium bicarbonate was 375 mg / tablet. One tablet was placed in a glass cup filled with 200 ml of water at room temperature, and the tablet effervescent for about 2.5 minutes. A little manganese carbonate precipitate was formed (less than in the previous example), and it redissolved after 3.5 minutes to obtain a clear solution with a slightly sour taste.
[0413] in conclusion
[0414] This example demonstrates that granulating the sodium bicarbonate reduces the amount of precipitate formed and still provides a fast tablet dissolution time.
[0415] Example 17: Effervescent Tablet Granulated with Low Levels of Sodium Bicarbonate
[0416] Dry manganese chloride tetrahydrate (from Example 16), alanine, sodium bicarbonate particles (from Example 16), anhydrous citric acid and PEG6000 were mixed for 5 minutes. Magnesium stearate was added and mixed for 1 minute. The tablet was compressed on a single punch tablet press using a 20mm flat tool, wherein the tablet weight was 2420mg and the hardness was 85N. The content of manganese chloride tetrahydrate was 800mg / tablet, the content of alanine was 500mg / tablet and the content of sodium bicarbonate was 281mg / tablet. At room temperature a tablet was placed in a glass cup equipped with 200ml water, and the tablet effervescently for about 3 minutes. A little manganese carbonate precipitate was formed (like Example 16), and it redissolved after 4 minutes. The solution became milky white and bubbling.
[0417] Even with the addition of a small amount of magnesium stearate the solution looked poor.
[0418] Example 18: Effervescent Tablet Granulated with Low Levels of Sodium Bicarbonate
[0419] Dried manganese chloride tetrahydrate (from Example 16), alanine, dry vitamin D3 100SD / S, sodium bicarbonate granules (from Example 16), anhydrous citric acid and PEG6000 were mixed for 5 minutes. The tablets were compressed on a single punch tablet press using a 20 mm flat tool, where the tablet weight was 2440 mg and the hardness was 80 N. The content of manganese chloride tetrahydrate was 800 mg / tablet, the content of alanine was 500 mg / tablet, the content of vitamin D was 20 μg / tablet plus 20% excess and the content of sodium bicarbonate was 253 mg / tablet. A tablet was placed in a glass with 200 ml of water at room temperature, and the tablet effervescent for about 3 minutes. A little manganese carbonate precipitate was formed (like Example 16), and it redissolved after 4 minutes to obtain a clear solution. The level of sodium bicarbonate was reduced to slow down the effervescence to reduce the time from the end of effervescence to complete dissolution.
[0420]
[0421]
[0422] Table 4: Batch compositions of Examples 15 to 18, in grams.
[0423] Example 19: Comparison of disintegration time and time to clear solution between "effervescent tablet" and "stick pack formulation", depending on temperature
[0424] Material
[0425] The materials used in this study are listed below:
[0426] Effervescent tablets (see Table 4): Batch RD1901-7-T1
[0427] The stick pack formulation, for each dose, contains:
[0428] o L-Alanine - Batch: 1809009 (500 mg)
[0429] o Vitamin D3 dry powder - Batch: 1809013 (10 mg)
[0430] o Manganese chloride tetrahydrate - Batch: 1912002 (800 mg)
[0431] Tap water
[0432] The stick pack formulation is an oral dry powder formulation in which manganese chloride tetrahydrate (800 mg) is packaged in one stick pack and a homogenous blend of L-alanine (500 mg) and dry vitamin D3 powder (10 mg, corresponding to 800 IU) is packaged in another stick pack. The two-chamber form of manganese chloride tetrahydrate in one pack and L-alanine and dry vitamin D3 powder in another pack is referred to herein as a powder formulation.
[0433] The effervescent tablets used herein contain the following:
[0434]
[0435] Table 4. Composition of the effervescent tablets. Manganese chloride dihydrate (654.41 mg) was obtained from the drying of 800 mg of manganese chloride tetrahydrate.
[0436] Effect of temperature on disintegration time and time to clear solution
[0437] method
[0438] Two different formulations (i.e., effervescent tablets and powder formulations) were dissolved in 200 ml of water at three different temperatures, 5 ° C, 15 ° C, and 20 ° C. Stirring was not used for the effervescent tablets, but the powder formulation was stirred. Disintegration time (a small amount of visible particles) and time to form a clear solution (no visible particles) were measured. Three samples were tested for each formulation and temperature.
[0439] result
[0440] The test results are presented in Table 5. It should be noted that disintegration only applies to effervescent tablets. Figure 1 shows the effect of temperature on the disintegration time of effervescent tablets and the time to form a clear solution. At each temperature tested, the effervescent tablets disintegrated and dissolved completely faster than the powder formulation. In addition, the lower the temperature, the longer the time to disintegrate and dissolve completely.
[0441]
[0442]
[0443] Table 5: Time to disintegration and time to clear solution formation at different temperatures for effervescent tablet and powder formulations (volume 200 ml). N / A = Not applicable.
[0444] in conclusion
[0445] The test shows that the effervescent tablet of the present disclosure disintegrates faster than 5 minutes in 0.2L of water at temperatures between 5°C and 20°C, and disintegrates faster at higher temperatures. From a patient's perspective, a temperature of 5°C is preferred because a 5°C aqueous solution is more comfortable to drink. This test also shows that the time to dissolve the effervescent tablet is significantly shorter than the time to dissolve the powder formulation. Therefore, in the case of preparing an oral solution for MRI, a compressed solid composition performs better than a powder formulation.
[0446] Example 20: Comparison of disintegration time and time to clear solution between "effervescent tablet" and "stick pack formulation", depending on volume
[0447] method
[0448] Two different formulations (i.e., the effervescent tablet and the powder formulation of Example 19) were dissolved in 50 ml or 200 ml of 20°C water. No stirring was used for the effervescent tablet, while the powder formulation was stirred. The disintegration time (a small amount of visible particles) and the time to form a clear solution (no visible particles) were measured. Three samples were tested at different volumes for each formulation.
[0449] result
[0450] The results are presented in Table 6. It should be noted that disintegration only applies to the effervescent tablets. The effect of water volume is shown in Figure 2. As can be seen from the results, the volume within the studied range had no effect on disintegration time or time to form a clear solution. The effervescent tablets formed a clear solution, while the powder formulation had undissolved particulate matter.
[0451]
[0452] Table 6: Time to disintegration and time to clear solution formation at different volumes for effervescent tablet and powder formulations (at 20°C). N / A = Not applicable.
[0453] The results in Table 6 show the difference between the two formulations after 5 minutes in 50 ml or 200 ml of 20°C tap water.
[0454] in conclusion
[0455] This embodiment illustrates that, compared with two-chamber powder formulations, compressed solid compositions (effervescent tablets) show significantly faster and therefore more optimal solubility and disintegration rate. Therefore, in the case of preparing oral solutions for MRI, compressed solid compositions perform better than powder formulations. In addition, the volume between 50mL and 200mL has no significant effect on disintegration / dissolution time.
Claims
1. An effervescent MRI tablet, the tablet consisting of: a. between 0.5 g and 1.2 g of manganese(II) chloride tetrahydrate or an equimolar amount of the corresponding anhydrate or dihydrate; b. between 0.25 g and 0.75 g of L-alanine; c. one or more water-soluble excipients selected from PEG6000, isomalt and povidone, wherein at least one excipient is PEG6000; and d. an effervescent couple, wherein the effervescent couple comprises an alkaline component and an acidic component; The effervescent MRI tablet is used for preparing an oral solution suitable for magnetic resonance imaging (MRI).
2. An effervescent MRI tablet, the tablet consisting of: a. between 0.5 g and 1.2 g of manganese(II) chloride tetrahydrate or an equimolar amount of the corresponding anhydrate or dihydrate; b. between 0.25 g and 0.75 g of L-alanine; c. Vitamin D, wherein the vitamin D is vitamin D3; d. one or more water-soluble excipients selected from PEG6000, isomalt and povidone, wherein at least one excipient is PEG6000; and e. an effervescent couple, wherein the effervescent couple comprises an alkaline component and an acidic component; The effervescent MRI tablet is used for preparing an oral solution suitable for magnetic resonance imaging (MRI).
3. The effervescent MRI tablet according to claim 1 or 2, wherein the effervescent MRI tablet comprises between 0.6 g and 1 g of manganese (II) chloride tetrahydrate.
4. The effervescent MRI tablet according to claim 1 or 2, wherein the effervescent MRI tablet comprises 0.8 g of manganese (II) chloride tetrahydrate or an equimolar amount of the corresponding anhydrate or dihydrate.
5. The effervescent MRI tablet according to claim 1 or 2, wherein the effervescent MRI tablet provides a clear solution in water at room temperature in 8 minutes or less.
6. The effervescent MRI tablet of claim 1 or 2, wherein the effervescent MRI tablet provides a clear solution in 0.2 L of water at room temperature in 8 minutes or less without stirring or agitating the solution.
7. The effervescent MRI tablet according to claim 1 or 2, wherein the effervescent MRI tablet completely dissolves in water at room temperature in 8 minutes or less without stirring or agitating the solution.
8. The effervescent MRI tablet according to claim 1 or 2, wherein the effervescent MRI tablet disintegrates in water at room temperature in less than 3.0 minutes without any stirring or agitation of the solution.
9. The effervescent MRI tablet according to claim 1 or 2, wherein the effervescent MRI tablet disintegrates in 0.2 L of water at room temperature in less than 3.0 minutes without any stirring or agitation of the solution.
10. The effervescent MRI tablet according to claim 1 or 2, wherein the effervescent MRI tablet results in a pH between 2 and 7 in 0.2 L of water after complete dissolution of between 0.5 g and 1 g of manganese(II) chloride tetrahydrate or an equimolar amount of any corresponding manganese(II) salt.
11. The effervescent MRI tablet according to claim 1 or 2, wherein the effervescent MRI tablet has a mass between 1.8 g and 4.0 g.
12. The effervescent MRI tablet according to claim 1 or 2, wherein the effervescent MRI tablet comprises manganese (II) chloride dihydrate.
13. The effervescent MRI sheet according to claim 1 or 2, wherein the alkaline component is bicarbonate.
14. The effervescent MRI sheet according to claim 1 or 2, wherein the acidic component is citric acid.
15. The effervescent MRI sheet according to claim 1 or 2, wherein the effervescent couple consists of citric acid and sodium bicarbonate, and wherein the mass ratio between citric acid and sodium bicarbonate is at least 1.2 to 1.
16. The effervescent MRI sheet according to claim 2, wherein the effervescent MRI sheet consists of: a. Manganese chloride tetrahydrate, dihydrate or anhydrous; bL-alanine; c. Isomalt; d. Sodium bicarbonate; e. citric acid; f. Polyethylene glycol 6000 (PEG6000); g. povidone; and h. Vitamin D, wherein the vitamin D is vitamin D3.
17. The effervescent MRI sheet according to claim 1 or 2, which is used as a magnetic resonance imaging (MRI) contrast composition.
18. Use of the effervescent MRI tablet according to claim 1 or 2 for preparing an oral solution.
19. A kit of parts, comprising: a) the effervescent MRI tablet according to claim 1 or 2; and b) Waterproof packaging.
20. A method for preparing the effervescent MRI tablet according to claim 1, wherein the method comprises the following steps: a) providing a physiologically acceptable manganese(II) compound, optionally in the form of particles, and optionally drying the physiologically acceptable manganese(II) compound; b) providing L-alanine; c) providing one or more water-soluble excipients that allow compression, the water-soluble excipients being selected from PEG6000, isomalt and povidone, wherein at least one excipient is PEG6000; d) mixing the physiologically acceptable manganese (II) compound with L-alanine and the one or more water-soluble excipients and the effervescent couple to provide a water-soluble mixture; and e) compressing the water-soluble mixture to provide the effervescent MRI tablet according to claim 1, The relative humidity (RH) was maintained below 30%.
21. A method for preparing the effervescent MRI tablet according to claim 2, wherein the method comprises the following steps: a) providing a physiologically acceptable manganese(II) compound, optionally in the form of particles, and optionally drying the physiologically acceptable manganese(II) compound; b) providing L-alanine and vitamin D, wherein the vitamin D is vitamin D3; c) providing one or more water-soluble excipients that allow compression, the water-soluble excipients being selected from PEG6000, isomalt and povidone, wherein at least one excipient is PEG6000; d) mixing the physiologically acceptable manganese (II) compound with L-alanine and vitamin D and the one or more water-soluble excipients and effervescent couple to provide a water-soluble mixture; and e) compressing the water-soluble mixture to provide the effervescent MRI tablet according to claim 2, The relative humidity (RH) was maintained below 30%.
22. An effervescent MRI tablet prepared by the process defined in any one of claims 20-21.
23. A method for preparing an oral MRI solution, the method comprising: a. providing an effervescent MRI tablet according to claim 1 or 2, b. Provide adequate water, and c. adding the effervescent MRI tablet to the water, Thereby forming the oral MRI solution.
